Skip to main content

Passage BIO, Inc.

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

PASG$3.78+10.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Statements of Operations and Comprehensive Loss

​​​​​​​​​​​​​
​ · ​ · Three Months Ended June 30, · ​ · Six Months Ended June 30,
(in thousands, except share and per share data) · ​ ​ ​ · 2026 · ​ ​ ​ · 2025 · ​ · 2026 · ​ ​ ​ · 2025
Operating expenses: · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
Research and development​$3,343​$5,814​$7,436​$13,551
General and administrative​6,873​4,520​11,660​10,605
Impairment of long-lived assets​​—​​—​​—​​2,637
Net gain on lease terminations​​(1,944)​​—​​(2,577)​​—
Loss from operations​(8,272)​(10,334)​(16,519)​(26,793)
Other income (expense), net​451​949​1,139​2,003
Net loss​$(7,821)​$(9,385)​$(15,380)​$(24,790)
Per share information:​​​​​​​​
Net loss per share of common stock, basic and diluted​$(2.44)​$(2.96)​$(4.80)​$(7.83)
Weighted average common shares outstanding, basic and diluted​3,208,744​3,168,933​3,207,313​3,166,437
Comprehensive loss:​​​​​​​​​​​​
Net loss​$(7,821)​$(9,385)​$(15,380)​$(24,790)
Unrealized gain (loss) on marketable securities​​—​​—​​—​​(8)
Comprehensive loss​$(7,821)​$(9,385)​$(15,380)​$(24,798)

See accompanying notes to unaudited interim consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.